• ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib.
    • Wilson Z, Odedra R, Wallez Y, Wijnhoven PWG, Hughes AM, Gerrard J, Jones GN, Bargh-Dawson H, Brown E, Young LA, O'Connor MJ, Lau A.
    • Cancer Res. 2022 Jan 25:canres.2997.2021. doi: 10.1158/0008-5472.CAN-21-2997. Epub ahead of print.